Thanks
@Little T. You would think at this point, the primary end point agreement with FDA is a given! They have been working on it for 6 months since the Oct end of phase 2 meeting with FDA
what I am more interested in is whether or not the management is able to follow up with Pitt Hopkins end of phase 2 meeting shortly after to progress to phase 3 quickly as opposed to waiting for months again! Angelman primary end point has already been set by the competitors so there should be no issue there.
Once all 3 indications are in phase 3 trials, it would be a very compelling proposition along with even 1 or 2 phase 2s for new indications
(20min delay)